Table 2.
Baseline characteristics of the two groups of patients based on whether they experienced CV or renal events during the follow-up period of the study.
| Variables | Patients Who ExperiencedCV or Renal Events | ||
|---|---|---|---|
| No | Yes | p Value | |
| Ν | 79 | 55 | |
| Women (N, %) | 25 (32) | 21(38) | 0.06 |
| Age (y) | 68 (56–76) | 68 (62–74) | 0.50 |
| BMI (kg/m2) | 28 (25.5–32) | 28 (26.5–32.4) | 0.31 |
| Baseline eGFR (mL/min/1.73 m2) | 39 ± 12 | 25 ± 13 | 0.00 |
| CKD stages | |||
| 3a (N, %) | 31 (39) | 7 (13) | 0 |
| 3b (N, %) | 30 (38) | 10 (19) | 0.02 |
| 4 (N, %) | 17 (22) | 27 (49) | 0 |
| 5 (N, %) | 1 (1) | 11 (20) | 0 |
| Diabetes (N, %) | 25 (32) | 24 (44) | 0.16 |
| Number of antihypertensive drugs used | 1.9 ± 1 | 2.7 ± 1.2 | 0.00 |
| RAS blockade (N, %) | 57 (72) | 35 (64) | 0.09 |
| iPTH (pg/mL) | 94 (60–116) | 152 (99–230) | 0.00 |
| Albumin-to-creatinine ratio (mg/g) | 64 (19–309) | 546 (161–1345) | 0.00 |
| Blood pressure (mm Hg) | |||
| Systolic OBP | 149 ± 19 | 153 ± 22 | 0.20 |
| Diastolic OBP | 83 ± 11 | 84 ± 14 | 0.54 |
| Systolic AOBP | 131 ± 15 | 136 ± 19 | 0.13 |
| Diastolic AOBP | 76 ± 11 | 78 ± 13 | 0.57 |
| Systolic daytime ABPM | 129 ± 15 | 135 ± 16 | 0.02 |
| Diastolic daytime ABPM | 76 ± 11 | 78 ± 12 | 0.35 |
| Systolic night-time ABPM | 118 ± 15 | 128 ± 19 | 0.00 |
| Diastolic night-time ABPM | 66 ± 11 | 69 ± 11 | 0.18 |
| Systolic 24 h ABPM | 125 ± 14 | 133 ± 17 | 0.00 |
| Diastolic 24 h ABPM | 73 ± 10 | 75 ± 11 | 0.23 |
ABPM—ambulatory blood pressure measurement; AOBP—automated office blood pressure; BMI—body mass index; CKD—chronic kidney disease; eGFR—estimated glomerular filtration rate; OBP—office blood pressure; RAS—renin–aldosterone system. Data are presented as the mean ± SD or median (interquartile range) for continuous variables and a percentage for categorical variables.